Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study
RC48, particularly in combination regimens, demonstrates promising efficacy in advanced NSCLC with <i>HER2</i> alterations. These findings underscore the need for further research to validate RC48's application in clinical practice.
Authors
- Meiling Zhang (ORCID: https://orcid.org/0000-0002-1023-8827)
- Jiu Yang
- Xiaoyou Li (ORCID: https://orcid.org/0000-0002-0307-3534)
- Kaihua Lu (ORCID: https://orcid.org/0000-0003-4744-4824)
- Qian Wang (ORCID: https://orcid.org/0000-0002-1346-9524)
- Meiqi Shi (ORCID: https://orcid.org/0000-0002-3578-4082)
- Wei Peng (ORCID: https://orcid.org/0000-0002-9463-2169)
- Li Wang (ORCID: https://orcid.org/0000-0002-0496-9500)
Institutions
- Jiangsu Cancer Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.3389/fonc.2024.1441025
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Natural Science Foundation of China